Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine
| Autor: | D. Bhatnager, D. R. Matthews, G. R. Evans, Jim Mann, H. Flax, N. Lewis-Barned, R. H. Jay, Paul N. Durrington, D. J. Betteridge, R. F. Bing |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Cholestyramine Resin Placebo-controlled study Hyperlipoproteinemia Type II chemistry.chemical_compound High-density lipoprotein Double-Blind Method Internal medicine medicine Humans Triglycerides General Environmental Science Aged Pravastatin Cholestyramine Triglyceride Cholesterol business.industry Cholesterol HDL General Engineering General Medicine Cholesterol LDL Middle Aged Endocrinology Treatment Outcome chemistry General Earth and Planetary Sciences Female lipids (amino acids peptides and proteins) business Lipoprotein medicine.drug Research Article |
| Popis: | OBJECTIVE--To compare the efficacy and safety of cholestyramine, an anion exchange resin, and pravastatin, a new hydrophilic specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in the treatment of heterozygous familial hypercholesterolaemia. DESIGN--Double blind, double dummy, placebo controlled study with three parallel groups. SETTING--Six specialist lipid clinics in the United Kingdom. PATIENTS--128 patients aged 18-70 with heterozygous familial hypercholesterolaemia diagnosed on strict biochemical and clinical findings. MAIN OUTCOME MEASURES--Total plasma cholesterol, triglyceride, and lipoprotein subfractions and biochemical and haematological safety parameters. RESULTS--Pravastatin (40 mg/day) led to a 25% reduction in total plasma cholesterol concentration and a reduction in low density lipoprotein cholesterol concentration of 30%. Cholestyramine (24 g/day) led to similar reductions in concentrations of total cholesterol (23%) and low density lipoprotein cholesterol (31%). No consistent changes occurred in high density lipoprotein cholesterol values with either compound. Plasma triglyceride concentrations showed a small rise (18%) on resin therapy. No serious adverse drug reactions occurred during the study. CONCLUSIONS--Pravastatin seems to be a highly effective, well tolerated drug for severe hypercholesterolaemia. Patients chosen for this study were recruited on the basis that they could tolerate a full dose of cholestyramine, and in this situation cholestyramine was also highly effective in lowering plasma low density lipoprotein cholesterol concentrations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|